The Role of Plasma Chromogranin A as Assessment of Treatment Response in Grade 1-3 Non-Functioning Gastroenteropancreatic (GEP) Neuroendocrine Tumors

#832

Introduction: Chromogranin A (CgA) is considered to be of value not only in diagnosis but also in monitoring the disease response to treatment. However, only a few studies have been published on this issue.

Aim(s): We investigated to evaluate whether biochemical response using plasma CgA level is in reliable concordance with the clinical response in grade 1-3 nonfunctiong gastroenteropancreatic neuroendocrine tumors (GEP-NETs) irrespective of chemotherapeutic agents.

Materials and methods: A total of 27 cases in 18 patients were enrolled in this study between March 2011 and September 2013. Twenty-seven cases were evaluated clinically and radiologically while serial CgA tests were also estimated during treatment.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Park Y

Authors: Park Y, Kim S, Lee J, Park S, Park J,

Keywords: CgA, gastroenteropancreatic neuroendocrine tumor,